A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Atrasentan (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 01 Apr 2026 New trial record